SIWA Therapeutics
Business Services · Illinois, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
400 E Randolph St Ste 705, Chicago, Illi...Phone Number
(312) 445-8529Website
www.siwatherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About SIWA Therapeutics
SIWA Therapeutics, Inc. is focused on treating aggressive cancers and other life-threatening diseases that should be eligible for FDA fast-tracking. SIWA's proprietary humanized monoclonal antibody, 318H, selectively targets cells with an abnormally high level of glycolysis (the Warburg effect) and oxidative stress. Targeted cells include specifically cancer cells, senescent cells, and virally and bacterially-infected cells. 318H binds to cancer cells, senescent cells and cells infected by SARS-CoV-2 (COVID-19) and Influenza A; testing of bacterially-infected cells is in progress. The company is partnering with a major institution in pancreatic cancer (a 318H in vivo PDX pancreatic cancer study in humanized mice is in process). Charles River Laboratories recently completed an in vivo 318H tolerability and pharmacokinetic studies in non-human primates in preparation for filing an IND application with the FDA. No adverse effects were observed.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SIWA Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on SIWA Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when SIWA Therapeutics launches new products
Click to see if SIWA Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at SIWA Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if SIWA Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if SIWA Therapeutics is spiking on competitors!
SIWA Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once SIWA Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined SIWA Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to SIWA Therapeutics
Compare insights from companies similar to SIWA Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
SIWA Therapeutics
<$5M
11-50
Private
-
2006
N/A
Company Profile Activity
Activity Insights
SIWA Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
SIWA Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about SIWA Therapeutics.
SIWA Therapeutics Tech Stack
A closer look at the technologies used by SIWA Therapeutics
See more technologies
SIWA Therapeutics News & Media
SIWA Therapeutics, Inc. Appoints Deborah Wince-Smith to Board of Directors
CHICAGO, Feb. 24, 2022 /PRNewswire/ -- SIWA THERAPEUTICS, INC, which has developed SIWA318H, a proprietary monoclonal antibody that has caused complete remission of pancreatic cancer in vivo in humanized mice, announced today that it has appointed Deborah Wince-Smith to its Board of...SIWA Therapeutics To Participate in September Investor Conferences
CHICAGO--(BUSINESS WIRE)-- #Pharma--SIWA Therapeutics will meet with investors to discuss development of monoclonal antibody into a broad-spectrum antiviral drug and cancer treatment.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding SIWA Therapeutics
Sign Up For FreeTo access detailed company insights
SIWA Therapeutics, Inc. is focused on treating aggressive cancers and other life-threatening diseases that should be eligible for FDA fast-tracking. SIWA's proprietary humanized monoclonal antibody, 318H, selectively targets cells with an abnormally high level of glycolysis (the Warburg effect) and oxidative stress. Targeted cells include specifica... Read More
